Cargando…
Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism
GITR is a TNF receptor, and its activation promotes immune responses and drives antitumor activity. The receptor is activated by the GITR ligand (GITRL), which is believed to cluster receptors into a high-order array. Immunotherapeutic agonist antibodies also activate the receptor, but their mechani...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880771/ https://www.ncbi.nlm.nih.gov/pubmed/35213218 http://dx.doi.org/10.1126/sciadv.abm4552 |
_version_ | 1784659303494320128 |
---|---|
author | He, Changhao Maniyar, Rachana R. Avraham, Yahel Zappasodi, Roberta Rusinova, Radda Newman, Walter Heath, Heidi Wolchok, Jedd D. Dahan, Rony Merghoub, Taha Meyerson, Joel R. |
author_facet | He, Changhao Maniyar, Rachana R. Avraham, Yahel Zappasodi, Roberta Rusinova, Radda Newman, Walter Heath, Heidi Wolchok, Jedd D. Dahan, Rony Merghoub, Taha Meyerson, Joel R. |
author_sort | He, Changhao |
collection | PubMed |
description | GITR is a TNF receptor, and its activation promotes immune responses and drives antitumor activity. The receptor is activated by the GITR ligand (GITRL), which is believed to cluster receptors into a high-order array. Immunotherapeutic agonist antibodies also activate the receptor, but their mechanisms are not well characterized. We solved the structure of full-length mouse GITR bound to Fabs from the antibody DTA-1. The receptor is a dimer, and each subunit binds one Fab in an orientation suggesting that the antibody clusters receptors. Binding experiments with purified proteins show that DTA-1 IgG and GITRL both drive extensive clustering of GITR. Functional data reveal that DTA-1 and the anti-human GITR antibody TRX518 activate GITR in their IgG forms but not as Fabs. Thus, the divalent character of the IgG agonists confers an ability to mimic GITRL and cluster and activate GITR. These findings will inform the clinical development of this class of antibodies for immuno-oncology. |
format | Online Article Text |
id | pubmed-8880771 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Association for the Advancement of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-88807712022-03-10 Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism He, Changhao Maniyar, Rachana R. Avraham, Yahel Zappasodi, Roberta Rusinova, Radda Newman, Walter Heath, Heidi Wolchok, Jedd D. Dahan, Rony Merghoub, Taha Meyerson, Joel R. Sci Adv Biomedicine and Life Sciences GITR is a TNF receptor, and its activation promotes immune responses and drives antitumor activity. The receptor is activated by the GITR ligand (GITRL), which is believed to cluster receptors into a high-order array. Immunotherapeutic agonist antibodies also activate the receptor, but their mechanisms are not well characterized. We solved the structure of full-length mouse GITR bound to Fabs from the antibody DTA-1. The receptor is a dimer, and each subunit binds one Fab in an orientation suggesting that the antibody clusters receptors. Binding experiments with purified proteins show that DTA-1 IgG and GITRL both drive extensive clustering of GITR. Functional data reveal that DTA-1 and the anti-human GITR antibody TRX518 activate GITR in their IgG forms but not as Fabs. Thus, the divalent character of the IgG agonists confers an ability to mimic GITRL and cluster and activate GITR. These findings will inform the clinical development of this class of antibodies for immuno-oncology. American Association for the Advancement of Science 2022-02-25 /pmc/articles/PMC8880771/ /pubmed/35213218 http://dx.doi.org/10.1126/sciadv.abm4552 Text en Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY). https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution license (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Biomedicine and Life Sciences He, Changhao Maniyar, Rachana R. Avraham, Yahel Zappasodi, Roberta Rusinova, Radda Newman, Walter Heath, Heidi Wolchok, Jedd D. Dahan, Rony Merghoub, Taha Meyerson, Joel R. Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism |
title | Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism |
title_full | Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism |
title_fullStr | Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism |
title_full_unstemmed | Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism |
title_short | Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism |
title_sort | therapeutic antibody activation of the glucocorticoid-induced tnf receptor by a clustering mechanism |
topic | Biomedicine and Life Sciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880771/ https://www.ncbi.nlm.nih.gov/pubmed/35213218 http://dx.doi.org/10.1126/sciadv.abm4552 |
work_keys_str_mv | AT hechanghao therapeuticantibodyactivationoftheglucocorticoidinducedtnfreceptorbyaclusteringmechanism AT maniyarrachanar therapeuticantibodyactivationoftheglucocorticoidinducedtnfreceptorbyaclusteringmechanism AT avrahamyahel therapeuticantibodyactivationoftheglucocorticoidinducedtnfreceptorbyaclusteringmechanism AT zappasodiroberta therapeuticantibodyactivationoftheglucocorticoidinducedtnfreceptorbyaclusteringmechanism AT rusinovaradda therapeuticantibodyactivationoftheglucocorticoidinducedtnfreceptorbyaclusteringmechanism AT newmanwalter therapeuticantibodyactivationoftheglucocorticoidinducedtnfreceptorbyaclusteringmechanism AT heathheidi therapeuticantibodyactivationoftheglucocorticoidinducedtnfreceptorbyaclusteringmechanism AT wolchokjeddd therapeuticantibodyactivationoftheglucocorticoidinducedtnfreceptorbyaclusteringmechanism AT dahanrony therapeuticantibodyactivationoftheglucocorticoidinducedtnfreceptorbyaclusteringmechanism AT merghoubtaha therapeuticantibodyactivationoftheglucocorticoidinducedtnfreceptorbyaclusteringmechanism AT meyersonjoelr therapeuticantibodyactivationoftheglucocorticoidinducedtnfreceptorbyaclusteringmechanism |